Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal Comirnaty in Elderly
NCT05977127Phase 2Terminated
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2023
- Primary completion
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of tozinameran in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Radboud University Medical Center. Primary endpoint: Concentrations of SARS-CoV-2-Spike protein specific IgG antibodies in serum at 28 days. Started Sep 2023; status: terminated.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05977127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05977127.